These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 17532813)

  • 21. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
    Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
    J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression.
    Kristiansen TB; Pedersen AG; Eugen-Olsen J; Katzenstein TL; Lundgren JD
    Scand J Infect Dis; 2005; 37(11-12):890-901. PubMed ID: 16308226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender differences in HIV drug resistance mutations and virological outcome.
    Mave V; Gahunia M; Frontini M; Clark R; Mushatt D
    J Womens Health (Larchmt); 2011 Jan; 20(1):117-22. PubMed ID: 21190485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
    Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
    Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.
    Maggiolo F; Airoldi M; Kleinloog HD; Callegaro A; Ravasio V; Arici C; Bombana E; Suter F
    HIV Clin Trials; 2007; 8(5):282-92. PubMed ID: 17956829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.
    Sigaloff KC; Ramatsebe T; Viana R; de Wit TF; Wallis CL; Stevens WS
    AIDS Res Hum Retroviruses; 2012 Feb; 28(2):171-5. PubMed ID: 21819219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed.
    Perno CF; Cozzi-Lepri A; Forbici F; Bertoli A; Violin M; Stella Mura M; Cadeo G; Orani A; Chirianni A; De Stefano C; Balotta C; d'Arminio Monforte A;
    J Infect Dis; 2004 Jun; 189(11):1983-7. PubMed ID: 15143463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.
    Al Dhahry SH; Scrimgeour EM; Al Suwaid AR; Al Lawati MR; El Khatim HS; Al Kobaisi MF; Merigan TC
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1166-72. PubMed ID: 15588338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the dynamics and dependencies of accumulating mutations with applications to HIV drug resistance.
    Montazeri H; Günthard HF; Yang WL; Kouyos R; Beerenwinkel N;
    Biostatistics; 2015 Oct; 16(4):713-26. PubMed ID: 25979750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing and managing antiretroviral drug resistance.
    Kuritzkes DR
    AIDS Patient Care STDS; 2004 May; 18(5):259-73. PubMed ID: 15186710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
    Newman H; Breunig L; van Zyl G; Stich A; Preiser W
    J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
    Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
    Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.